Chemo-free regimen demonstrates efficacy in NSCLC europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.
Tulane’s efforts to treat, cure and prevent disease are not confined within the walls of the School of Medicine. Instead, the most exciting medical discoveries will happen across campuses and departments made possible by the teamwork of researchers in multiple schools and departments. Three School of Medicine investigators one who recently joined Tulane, one who has seven years of service to the university, and one who returned to Tulane shortly before the pandemic began show that the future of medicine hinges on capacity for collaboration, inside the lab and out.
GIOVANNI PIEDIMONTE, MD
Giovanni Piedimonte, MD, has always espoused a collaborative approach. Piedimonte, a practicing pediatric pulmonary physician, investigator and administrator who joined Tulane as vice president for research and institutional official, as well as a professor in the Department of Pediatrics, keeps an eye toward the evolution of medicine and physician education.
COVID-19 Vaccine Janssen Description
The Johnson and Johnson Janssen COVID-19 single-shot experimental vaccine leverages Janssen s AdVac and PER.C6® technologies. Janssen’s AdVac® vectors are based on a specific type of adenovirus, which has been genetically modified so that it can no longer replicate in humans and cause disease. Adenoviruses are a group of viruses that can cause the common cold.
The AdVac® technology works by using an adenovirus as a vector (a carrier) of an antigen’s genetic code to mimic components of a pathogen (a bacterium, virus, or other disease-causing organisms). Antigens (components of a pathogen) are produced to mimic the pathogen without causing severe disease.
of
LEXINGTON, Ky. (March 4, 2021) March marks one year since the COVID-19 global pandemic disrupted and altered everyone’s life.
On March 6, it will be a year since Kentucky confirmed the first case of COVID-19 – a patient admitted to UK Chandler Hospital. A few days later, on March 11, the University of Kentucky announced it would transition its campus of more than 30,000 students to online instruction – initially just for two weeks following spring break but eventually from March 23 through the end of the Spring 2020 semester.
Additionally, on March 20, UK President Eli Capilouto announced all employees able to work remotely would begin to do so, except for those in patient care, public safety, facilities maintenance and other areas where work must be performed on-site. Seemingly overnight, the bustling campus became desolate.
Jan. 29, 2021
Dr. Richard Greenberg and Linda Rice, director of Clinical Operations for the UK Center for Clinical and Translational Science
LEXINGTON, Ky. (Jan. 29, 2020) – The University of Kentucky, in partnership with Baptist Health Lexington and Norton Healthcare in Louisville, participated as a site for the Janssen Pharmaceutical Companies of Johnson & Johnson’s Phase 3 clinical research study, called the ENSEMBLE trial, to evaluate Janssen’s investigational COVID-19 vaccine candidate, JNJ-78436735, also known as Ad26.COV2.S. The results of the trial were released today.
The Phase 3 randomized, double-blind, placebo-controlled clinical trial was designed to evaluate the safety and efficacy of a single vaccine dose of the Janssen investigational COVID-19 vaccine candidate versus placebo. Approximately 45,000 people participated worldwide. The combined UK, Baptist and Norton site was among the top enrolling sites in the world.